Nevirapine

證據等級: L5

預測適應症: 3 個

Nevirapine: From HIV-1 Infection to Simian Immunodeficiency Virus (SIV) Infection

One-Sentence Summary

Nevirapine is a first-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) established for HIV-1 antiretroviral therapy (this evidence pack contains no SAHPRA regulatory record confirming a local original indication). The TxGNN model predicts it may be effective for simian immunodeficiency virus (SIV) infection, with no clinical trials and 17 preclinical/mechanistic publications currently associated with this direction — and several of those publications actually report NNRTI resistance in SIV.

Quick Overview

Item	Content
Original Indication	HIV-1 infection (NNRTI antiretroviral) — general pharmacological knowledge; not confirmed by any SAHPRA registration record in this evidence pack
Predicted New Indication	Simian immunodeficiency virus (SIV) infection
TxGNN Prediction Score	99.85%
Evidence Level	L4
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (data gap DG002). Based on known pharmacology, nevirapine is a first-generation NNRTI that binds a hydrophobic pocket specific to HIV-1 reverse transcriptase (RT), blocking viral replication; its efficacy in HIV-1 infection is well established.

SIV and HIV-1 belong to the same “immunodeficiency virus” family and share substantial sequence and structural homology, which plausibly explains why the TxGNN knowledge-graph embedding clustered them together and produced a high similarity score. However, the underlying literature evidence undermines this prediction mechanistically: two in vitro resistance-profiling studies (PMID 7541200, PMID 15040537) specifically report that native SIV and HIV-2 RT are largely resistant to first-generation NNRTIs such as nevirapine, because the NNRTI binding pocket is not well conserved outside HIV-1 RT. The chimeric/humanized SIV models that do respond to nevirapine (e.g., RT-SHIV constructs, PMID 15564466, 19195672, 11375059) do so only because they carry an engineered HIV-1 RT gene, not native SIV RT.

Taken together, this prediction is best read as a knowledge-graph clustering artifact driven by disease-entity similarity rather than genuine pharmacological plausibility against wild-type SIV. SIV infection is also primarily a non-human primate research/veterinary model used to study HIV pathogenesis and drug resistance, not a recognized human clinical indication.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

PMID	Year	Type	Journal	Key Findings
7541200	1995	In vitro resistance profiling	Biochem Biophys Res Commun	Chimeric SIV carrying HIV-1 RT is sensitive to NNRTIs, but native SIV RT is not — indicates NNRTI specificity for HIV-1 RT
15040537	2004	In vitro susceptibility comparison	Antiviral Therapy	Evaluated 16 approved anti-HIV-1 drugs against HIV-2, SIV and SHIV strains; informs treatment/PEP applicability across strains
15564466	2004	In vitro chimeric virus characterization	Journal of Virology	Characterized SIV-HIV chimera expressing HIV-1 RT to study NNRTI antiviral resistance in pigtail macaques
19195672	2009	Animal model (macaque) transmission study	Virology	RT-SHIV (HIV-1 RT in SIV backbone) transmits efficiently via vaginal route in rhesus macaques, supporting its use as a resistance-study model
11375059	2001	Animal model resistance development	AIDS Research and Human Retroviruses	RT-SHIV-infected cynomolgus monkeys used to study emergence/reversal of RT-inhibitor drug resistance in vivo
12234864	2002	In vitro combination study	Antimicrob Agents Chemother	Diketo integrase-inhibitor derivative tested in combination with zidovudine, nevirapine, or nelfinavir against SIV(MAC251); combinations were subsynergistic
11020686	2000	Review/clinical commentary (non-SIV)	Annals of Emergency Medicine	Reviews nonoccupational HIV post-exposure prophylaxis; cites animal SIV studies as indirect support, not direct nevirapine-SIV data
27748043	2017	In vitro antiviral screening	Chemical Biology & Drug Design	Novel small molecule 3G11 blocks HIV-1 RT but does not inhibit SIV(mac), HIV-2, or other lentiviruses — illustrates HIV-1 RT specificity
9875393	1998	In vitro antiviral screening	Antiviral Chemistry & Chemotherapy	Fluoroquinolone derivative K-12 shows broad-spectrum activity against HIV-1, HIV-2 and SIV strains at the transcriptional level
16859727	2006	In vitro virion pretreatment study	Virology	HIV-1 and SIV virions pretreated with NRTIs/NNRTIs to test inhibition of endogenous reverse transcription as a potential microbicide strategy

South Africa Market Information

No SAHPRA-registered products for nevirapine are recorded in this evidence pack (0 registrations; market status: Not marketed). Regulatory/product-level data (registration numbers, brand names, approved indication text) is a data gap (DG001, Blocking) and must be sourced from the SAHPRA register/PI directly before any repurposing pathway can proceed.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale:

Evidence is limited to preclinical/mechanistic studies (L4) with no clinical trials, and the strongest mechanistic evidence (PMID 7541200, 15040537) indicates that wild-type SIV reverse transcriptase is naturally resistant to first-generation NNRTIs like nevirapine — the high TxGNN score likely reflects disease-entity clustering (“immunodeficiency virus” family) rather than true pharmacological plausibility. SIV is also not a human clinical indication. The two lower-ranked candidates in this pack (feline immunodeficiency syndrome — a veterinary indication with a single structural-comparison paper; and a rare neurodevelopmental white-matter disorder — L5, no supporting evidence at all) are equally unsupported and also recommended Hold.

To proceed, the following is needed:

SAHPRA-approved Professional Information (PI) — warnings, contraindications, DDI (blocking data gap DG001)
Confirmed mechanism of action detail from DrugBank/primary literature (DG002)
A validated human-relevant target indication, since SIV infection itself has no human clinical application
If pursuing a genuine HIV/AIDS-adjacent repurposing hypothesis, re-run prediction/evidence review against clinically relevant disease terms (e.g., specific opportunistic infections or HIV treatment-adjacent conditions) rather than the animal-model entity “SIV infection”
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.